Home Featured Page 108

Featured

Latest

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Looking Ahead to a Psychedelic 2023

PT393 – Religious Freedom and the Church of Psilomethoxin

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial...

Opinions | Do Mice Hallucinate? Do Humans Head-Twitch?

Numinus to Participate in a Water Tower Research Fireside Chat on...

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

PT392 – Vital Psychedelic Conversations

Transcend Therapeutics announces Series A funding round of $40 million

The Psychedelic Educators Network

1...107108109...303 Page 108 of 303

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Looking Ahead to a Psychedelic 2023

PT393 – Religious Freedom and the Church of Psilomethoxin

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial...

Opinions | Do Mice Hallucinate? Do Humans Head-Twitch?

Numinus to Participate in a Water Tower Research Fireside Chat on...

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

PT392 – Vital Psychedelic Conversations

Panel: Psychedelic Careers

Transcend Therapeutics announces Series A funding round of $40 million

The Psychedelic Educators Network

EDITOR PICKS

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY